About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
E
AACR 2024 Insights: "Escape Mechanisms Associated With T-Cell Engagers in Myeloma"
By
Ernesta Paola Neri
2 Videos
0 views
May 20, 2024
Comments
0
Login to view comments.
Click here to Login
Featured Video
01:29
Incyte
Targeting CSF-1R to Manage Inflammation and Fibrosis in GVHD
Featured Video
16:51
Incyte
Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk
Feat.
C. Harrison
Recommended
AUTOPLAY
ON
Related
Newest
17:52
Indy Hematology Review
2024 Updates on Emerging & Current Treatment of Multiple Myeloma
Feat.
K. Anderson
16:42
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "The Best of Myeloma - Highlights & Key T…
Feat.
H. Hashmi
19:08
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGU…
Feat.
R. Banerjee
24:23
MyCancerHaven
Will CAR-Ts and Bispecifics Will Replace HSCT in Myeloma?
Feat.
R. Vij,
S. Al Hadidi
24:35
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "The Best of Myeloma - Review of the Top 5 …
Feat.
H. Hashmi
24:44
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignan…
Feat.
R. Birhiray
09:51
i3 Health
MRD Testing in Leukemias: When Negativity Is a Positive Thing
Feat.
N. S. Raje
13:47
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "MRD2STOP Study - Discontinuation of Maint…
Feat.
B. Derman
05:35
Saurabh Chhabra
Bispecifics & CAR-Ts in MM: How to Choose and How to Sequence
20:19
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Highlights of Hematologic Malignancies - …
Feat.
A. Paulus
36:10
Insights from 2024 EHA Annual Meeting
Highlights in Plasma Cell Disorders From ASCO® and EHA
Feat.
S. Al Hadidi
12:38
SOHO 2022 Tenth Annual Meeting
SOHO 2022 DEBATE: Bispecific Antibodies vs. CAR-T for R/R MM - Defen…
Feat.
S. Usmani
35:37
University of Colorado Division of Hematology
2024 Updates on Multiple Myeloma Treatment
Feat.
D. Sherbenou
26:46
Samer Al Hadidi
CAR-Ts Earlier in MyelomaTherapy?: What We Learned From the Recent F…
14:09
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Summary: "Multiple Myeloma Highlights and Clinical P…
Feat.
H. Hashmi
03:42
Moffitt Cancer Center
Multiple Myeloma: What You Need to Know About New FDA Approvals of C…
Feat.
D. Hansen
35:27
Dana-Farber Cancer Institute
Advances in Multiple Myeloma 2024: From Bench to Bedside
Feat.
K. Anderson
17:07
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "Comparative Review of Toxicities and Their…
Feat.
M. Minnema
08:30
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "DREAMM-7 Trial - BelamafVd vs. DaraVd in …
Feat.
M. Mateos
27:11
MyCancerHaven
POEMS Syndrome Management
Feat.
R. Vij,
D. Dingli
